Blockchain Registration Transaction Record

First-ever guideline targets cardiovascular-kidney-metabolic syndrome

First-ever guideline on cardiovascular-kidney-metabolic syndrome from AHA and ACC outlines staging, prevention, and treatment including GLP-1 therapies and lifestyle changes.

This guideline matters because it provides a unified framework to address the intertwined epidemics of obesity, diabetes, kidney disease, and heart disease. For readers, it means earlier detection and personalized prevention strategies, potentially reversing disease progression and reducing the risk of heart attack, stroke, or kidney failure. By emphasizing lifestyle changes and new medications like GLP-1 therapies, it empowers individuals to take control of their health and highlights the critical need for coordinated care across specialties.